.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Check market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 8,524,276

« Back to Dashboard
Patent 8,524,276 protects RELISTOR and is included in one NDA. There have been three Paragraph IV challenges on Relistor.

This patent has twenty-four patent family members in twenty-two countries.

Summary for Patent: 8,524,276

Title:Oral formulations and lipophilic salts of methylnaltrexone
Abstract: The present invention provides compositions comprising methylnaltrexone or a salt thereof, and compositions and formulations thereof, for oral administration.
Inventor(s): Shah; Syed M. (Delray Beach, FL), Diorio; Christopher Richard (Campbell Hall, NY), Ehrnsperger; Eric C. (New City, NY), Meng; Xu (San Diego, CA), Al Shareffi; Kadum A. (Greensboro, NC), Cohen; Jonathan Marc (Monroe, NY)
Assignee: Wyeth, LLC (Madison, NJ)
Application Number:13/045,108
Patent Claim Types:
see list of patent claims
Composition; Compound; Dosage form; Formulation; Device;
Patent Metrics:
Source: PatentQuant.com
Field: Pharmaceuticals
Back Citations: 0th percentile
Forward Citations: 1st percentile

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Salix Pharms Inc
RELISTOR
methylnaltrexone bromide
TABLET;ORAL208271-001Jul 19, 2016RXYesYes8,524,276► subscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Server shutdown in progress